naltrexone has been researched along with triazoles in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kranzler, HR; Modesto-Lowe, V; Van Kirk, J | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Kuehn, BM | 1 |
| Beaver, J; Bullmore, ET; Bush, MA; Gunn, RN; Hill, S; Howard, J; Long, C; Makwana, A; Matthews, PM; Miller, SR; Nathan, PJ; Newbould, RD; Passchier, J; Rabiner, EA; Reiley, R; Searle, G | 1 |
| Bullmore, ET; Everitt, BJ; Giuliano, C; Nathan, PJ; Robbins, TW | 1 |
| Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Podhaizer, EM; Zhang, Y | 1 |
| Bullmore, ET; Felici, A; Henderson, G; Kelly, E; Maltby, K; Mundell, SJ; Nathan, PJ; Roth, AL; Sava, A | 1 |
| Belin, D; Bullmore, ET; Economidou, D; Everitt, BJ; García-Pardo, MP; Giuliano, C; Goodlett, CR; Robbins, TW | 1 |
| Bullmore, ET; Maltby, K; Miller, SR; Mugnaini, M; Nathan, P; Ripley, TL; Sanchez-Roige, S; Stephens, DN; Wille, DR | 1 |
| Bullmore, ET; Dodds, C; Fernando, D; Fletcher, PC; Hosking, LK; Korzeniowska, A; Maltby, K; Miller, SR; Nathan, PJ; Nestor, LJ; Richards, DB; Sarai, BK; Subramaniam, N; Vasist Johnson, L; Warren, L; Waterworth, D; Win, B; Ziauddeen, H | 1 |
| Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y | 1 |
1 review(s) available for naltrexone and triazoles
| Article | Year |
|---|---|
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
3 trial(s) available for naltrexone and triazoles
| Article | Year |
|---|---|
Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Piperazines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Triazoles | 2000 |
Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Topics: Adult; Amygdala; Brain; Brain Mapping; Corpus Striatum; Dose-Response Relationship, Drug; Fentanyl; Food; Humans; Indans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Radioligand Assay; Radionuclide Imaging; Reward; Triazoles | 2011 |
Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Topics: Adolescent; Adult; Aged; Alanine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drinking; Eating; Female; Glycine; Humans; Indans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Triazoles; Young Adult | 2016 |
8 other study(ies) available for naltrexone and triazoles
| Article | Year |
|---|---|
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Findings on alcohol dependence point to promising avenues for targeted therapies.
Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline | 2009 |
Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Topics: Animals; Avoidance Learning; Binge-Eating Disorder; Conditioning, Operant; Feeding Behavior; Female; Food Preferences; Indans; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, mu; Reinforcement Schedule; Synaptic Transmission; Triazoles | 2012 |
A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
Topics: Astrocytes; Cells, Cultured; Cyclohexanes; Genes, Reporter; HIV Fusion Inhibitors; HIV-1; Humans; Luciferases; Maraviroc; Microglia; Naltrexone; Receptors, CCR5; Receptors, Opioid; Triazoles; Virus Internalization | 2013 |
The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Topics: Analgesics, Opioid; Animals; CHO Cells; Compulsive Behavior; Cricetinae; Cricetulus; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Indans; Ligands; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Protein Binding; Receptors, Opioid, mu; Reward; Treatment Outcome; Triazoles | 2015 |
The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Blood Alcohol Content; Choice Behavior; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Indans; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, mu; Reinforcement, Psychology; Species Specificity; Triazoles | 2015 |
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Autoradiography; Behavior, Animal; Central Nervous System Depressants; Cross-Over Studies; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Ethanol; Indans; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Radiopharmaceuticals; Receptors, Opioid, mu; Self Administration; Triazoles; Tritium | 2015 |
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles | 2016 |